<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00595244</url>
  </required_header>
  <id_info>
    <org_study_id>127-006</org_study_id>
    <nct_id>NCT00595244</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease</brief_title>
  <official_title>CSP 127-006 A Phase 3 Clinical Trial to Assess Perfusion and Obstruction Identified by Non-Invasive Technology Using PB127 Ultrasound Contrast Agent in Patients With Suspected Obstructive Coronary Arter Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Point Biomedical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Point Biomedical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is to compare PB127 echocardiography to other heart imaging studies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">October 2003</completion_date>
  <primary_completion_date type="Actual">October 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate the non-inferiority of the diagnostic performance of PB127 MCE versus stress SPECT in the detection and/or exclusion of significant obstructive CAD as defined by QCA or qualifying clinical outcome.</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the concordance of PB127 MCE with stress SPECT in differentiating between reversible vs. fixed defects in patients with significant obstructive CAD</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the diagnostic performance of PB127 MCE with stress SPECT in identifying the location of stenosis as identified by coronary angiography.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">456</enrollment>
  <condition>Coronary Artery Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PB127 for injectable suspension</intervention_name>
    <description>0.175 mg/kg diluted in 150 mL Dextrose in Water 5% in glass bottles to be infused at 250 mL/hour until stead state achieve, 150 mL/hour during rest image acquisition, and 100-150 mL/hr during stress image acquistion. Single IV infusion, not to exceed 60 minutes.</description>
    <other_name>CARDIOsphereÂ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Stratum 1:

          1. Able to provide written informed consent

          2. Low (less than 10%) pre-test probability of CAD (Appendix D)

          3. Scheduled for clinically indicated stress echocardiography or stress SPECT within the
             14 days prior to or following Study Day 1 (prior to coronary angiography) or coronary
             angiography within the 7 days following Study Day 1

          4. Technically adequate unreconstructed stress SPECT data or scheduled for clinically
             indicated stress SPECT within 14 days of Study Day 1 and prior to coronary angiography

          5. Adequate visualization of all myocardial segments in at least one view during
             non-contrast echocardiography (See Section 5.3.1)

          6. No evidence of a right-to-left shunt during non-contrast echocardiography

        Stratum 2:

          1. Able to provide written informed consent

          2. Intermediate (10% to 90%) pre-test probability of CAD (Appendix D)

          3. Scheduled for clinically indicated coronary angiography within the 7 days following
             Study Day 1

          4. Technically adequate unreconstructed stress SPECT data or scheduled for stress SPECT
             within 14 days of Study Day 1 and prior to coronary angiography

          5. Adequate visualization of all myocardial segments in at least one view during
             non-contrast echocardiography (See Section 5.3.1)

          6. No evidence of a right-to-left shunt during non-contrast echocardiography

        Stratum 3:

          1. Able to provide written informed consent

          2. High (greater than 90%) pre-test probability of CAD (Appendix D)

          3. Scheduled for clinically indicated coronary angiography within the 7 days following
             Study Day 1

          4. Technically adequate unreconstructed stress SPECT data or scheduled for stress SPECT
             within 14 days of Study Day 1 and prior to coronary angiography

          5. Adequate visualization of all myocardial segments in at least one view during
             non-contrast echocardiography (See Section 5.3.1)

          6. No evidence of a right-to-left shunt during non-contrast echocardiography

        Exclusion Criteria:

          1. Women who are pregnant or lactating

          2. Known hypersensitivity or known contraindication to:

               1. Dipyridamole

               2. Ultrasound contrast agents (including PB127 and excipients)

               3. Blood, blood products, albumin, egg, or protein

          3. Use of caffeine or xanthine containing products within the 24 hours prior to PB127 MCE

          4. Previous exposure to PB127 Ultrasound Contrast Agent

          5. Heart transplant

          6. Known right-to-left shunt including atrial septal defect

          7. Current or history of uncontrolled ventricular tachycardia

          8. Current atrial fibrillation, atrial tachycardia, or atrial flutter

          9. Pacemaker or defibrillator

         10. Unstable cardiac status

               1. Unstable angina grade CCS Class IV severity with ongoing symptoms and/or ongoing
                  infusion of intravenous nitroglycerin (See Appendix F)

               2. Second-degree or greater heart block

               3. Frequent (&gt;60/hour) or symptomatic ventricular ectopics at baseline

               4. Hypertension (SPB &gt;200 and/or DBP &gt;110 mmHg on two consecutive readings within
                  one hour of PB127 MCE)

               5. Hypotension (SPB &lt;90 mmHg)

               6. Severe aortic stenosis (&gt;100 mmHg peak transvalvar gradient or &lt;0.6 cm2 estimated
                  valve area)

               7. Pulmonary edema within the 7 days prior to Study Day 1

               8. Resting oxygen saturation of less than 90%

               9. Q-wave myocardial infarction within the 7 days prior to Study Day 1

              10. PTCA or CABG within the 7 days prior to Study Day 1

         11. Chronic Obstructive Pulmonary Disease (COPD) or bronchospastic airway disease which,
             in the opinion of the Investigator, is significant enough to contraindicate
             dipyridamole

         12. Known history of severe pulmonary hypertension characterized by estimated pulmonary
             artery systolic pressure of &gt;50 mmHg

         13. Use of intravenous or intracoronary contrast agent other than thallium or technetium
             within the 24 hours prior to Study Day 1

         14. Liver disease (i.e., current or previous hepatic viral infection, chronic hepatitis)
             characterized by one or more of the following

               1. Current jaundice

               2. Elevated bilirubin &gt; upper limit of normal

               3. Currently elevated hepatic enzymes &gt; 2X upper limit of normal

         15. Medical conditions or other circumstances that would significantly decrease the
             chances of obtaining reliable data or achieving the study objectives (i.e., drug
             dependence, psychiatric disorder, dementia, or associated illness), extenuating
             circumstances, medical conditions that make it unlikely that a patient can complete
             the clinical trial or follow-up evaluations, or other reasons for expected poor
             compliance with the Investigator's instructions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Ehlgen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>POINT Biomedical Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Michael Morgan, MD</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Beach VA Medical Center Cardiology Division</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Division of Cardiology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco VA Medical Center NCIRE</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center Cardiovascular Research Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Cardiovascular Studies Kramer &amp; Crouse Cardiology</name>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University Medical Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation Department of Cardiology</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cardiovascular Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Sciences Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center Department of Cardiology</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Cardiovascular Research Institute Spokane Cardiology</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2008</study_first_submitted>
  <study_first_submitted_qc>January 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2008</study_first_posted>
  <last_update_submitted>July 1, 2008</last_update_submitted>
  <last_update_submitted_qc>July 1, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2008</last_update_posted>
  <responsible_party>
    <name_title>Tom Ottoboni/Chief Operating Officer</name_title>
    <organization>POINT Biomedical Corp.</organization>
  </responsible_party>
  <keyword>Perfusion</keyword>
  <keyword>Echocardiograpy</keyword>
  <keyword>SPECT</keyword>
  <keyword>angiography</keyword>
  <keyword>Chest pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

